Novartis wins Swiss approval for Coartem Baby, first malaria drug for infants and young children

19 hours ago 3

• Healthcare

Veronique D

• Novartis (NYSE:NVS) on Tuesday said that Coartem (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants.
• The new treatment, also known as Riamet Baby in some countries, was developed in collaboration with Medicines for

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. Novartis wins Swiss approval for Coartem Baby, first malaria drug for infants and young children